바이오스펙테이터

바이오스펙테이터 Joungmin Cho 기자

Research Director, Kim Jung-ho introduces main pipeline at the 5th bio-investment forum held by Mirae Asset Daewoo

“Oscotec is focusing on finding 518 human kinases that have unmet needs, and it’s been 9 years since established a subsidiary, Genosco, in Boston where big pharma companies are located. We have tried our best efforts to develop new drugs to compete with them, and now, we are looking forward to seeing visible results soon.” Director of Research in Oscotec, Kim Jung-ho, said on the 13th at the 5th bio-Investment Forum.

Oscotec is a new drug developing company which has a pipeline being developed jointly with Yuhan, and has been conducting clinical trials for their own two pipelines in the U.S. and firstly announced their pipelines in the forum that was held jointly by Mirae Asset Daewoo and the Korea Bio Association.

Dr.Kim said, “Oscotec is a company that develops small-molecular-compound drugs and has patent (IP) rights to design and synthesize new compounds that are suitable for their own purposes. However, we are using the NRDO method outsourced with CRO for clinical developing processes.”

Oscotec is focusing on kinase. Phosphorylating enzymes are activated by ATP and continue to transmit signals to the sub-system. In abnormal conditions such as cancer, phosphorylating enzymes cause various problems by maintaining unnecessary activation.... <계속>